Harry Thomas Hall IV, known as I.V., is the current Managing Director/Chief Executive Officer of Next Science. I.V. has more than 28 years in the global medical device industry and has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. His diverse background and profound understanding of the industry make him the perfect fit to lead Next Science into the future.
I.V. holds a Bachelor of Science: Ceramic Engineering and Master of Science: Bioengineering from Clemson University, as well as an MBA from Pennsylvania State University. I.V. also completed the Advanced Management Program at Harvard Business School.
As the founder and CTO of Next Science, Dr. Matt Myntti oversees and manages all aspects of R&D and product ideation of Next Science technologies. He received his Master’s and Doctoral degrees in Materials Science and Engineering from the University of Dayton and has over 30 granted US patents. Dr. Myntti previously led the biomaterials group at Medtronic Surgical Technologies, which developed novel ENT and neurologic products.
Currently serving as Chief Strategy Officer, Jon Swanson joined the Next Science team in June 2018 as the Chief Operating Officer to lead the operations, quality and regulatory teams. Mr. Swanson joins us from McKinsey & Co., where as the Head of the Advanced Operations Group, he focused on client operational improvement, product development and quality performance for pharma and medical product industries since 2011.
Prior to that, Mr. Swanson spearheaded manufacturing, product development and operational excellence at Medtronic in multiple leadership roles. As a professional rooted in operations and nuclear engineering excellence, he started his career in the US Navy. He holds a Master’s Degree in Business Administration from the University of Florida and a Bachelor’s Degree in Mathematics from the US Naval Academy.
Marc Zimmerman is the Chief Financial Officer at Next Science. After a 16-year career at Verizon Wireless, which included roles as Vice President of Supply Chain for the Wireless operation, Master Black Belt in the Lean Six Sigma program, and Area CFO for the Northeast Area, he joined Actavo, headquartered in Dublin, Ireland, as the CFO for the US and Caribbean operation. Most recently, he was the CFO for Center for Transportation and the Environment.
Mr. Daniel Canon is the VP, Operations at Next Science. As the former Senior Engineering Manager at Medtronic, he managed strategic company acquisitions, development and execution of subsequent business integration strategies to assure top notch medical device production quality.
An industry veteran with over 20 years of experience, Mr. Canon has lead complex projects in military, commercial, defense and medical operational environments. He has a Bachelor’s Degree in Electrical Engineering from Pennsylvania State University and a Master’s Degree in Mechanical Engineering from the University of Maryland.
Jeanne Lee is the Vice President of Quality, Regulatory Affairs, and Clinical Operations at Next Science. Ms. Lee brings over 20 years of global regulatory experience within the medical device and pharmaceutical industries, gained at leading companies including Hollister Incorporated, Abbott Laboratories and Merck & Co. Inc. Ms. Lee holds a Master of Science degree in Regulatory Affairs and Quality Assurance from Temple University.
Robert “Rob” Bell is the Senior Vice President of Sales in North America for Next Science. Mr. Bell oversees the commercial operations via industry partners and direct sales channels in both the surgical and wound sectors. He is responsible for creating and implementing sales strategies, pursuing new business opportunities, and maintaining a strong sales pipeline and salesforce. Mr. Bell has held various leadership roles within orthopedics, establishing distribution and subsidiaries globally, bringing 14 years of experience in the Medical Device and Orthopedics industries.
Many Minds, One Focus
With diverse, proven experience in research and development and bringing innovative technologies to market, our team has championed medtech innovation through the years. We are committed to improving public health through groundbreaking and invaluable solutions backed by the latest in scientific research and discovery.
Board of Directors
Sharing the same values and goals as everyone at Next Science, the Board of Directors is comprised of industry executives with the knowledge, expertise and passion to help guide the company in fulfilling its mission.
Non-Executive Director
Non-Executive Director
Prior to joining Next Science, Aileen was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. She led Johnson & Johnson’s efforts to acquire Synthes for approximately $21 billion, Johnson & Johnson’s largest medical device acquisition. She also led the efforts to divest the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also involved in numerous other M&A transactions including Pfizer Consumer Healthcare (US$16.5 billion), Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. Aileen is a Non-Executive Director of Microbot Medical Inc. (NASDAQ: MBOT)
Harry Thomas Hall IV, known as I.V., is the current Managing Director/Chief Executive Officer of Next Science. I.V. has more than 28 years in the global medical device industry and has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. His diverse background and profound understanding of the industry make him the perfect fit to lead Next Science into the future.
I.V. holds a Bachelor of Science: Ceramic Engineering and Master of Science: Bioengineering from Clemson University, as well as an MBA from Pennsylvania State University. I.V. also completed the Advanced Management Program at Harvard Business School.
Grant was part of Next Science’s ASX listing deal team in 2019. He has been a partner of a major Australian law firm for over fifteen years. Grant has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients. Grant has been a non-executive director of GLG Corp Ltd (ASX:GLE)(GLG) since 2018 and serves as the Chair of GLG’s Nomination and Remuneration Committee and as a member of GLG’s Audit and Risk Committee. Grant holds a Bachelor of Science with an honours degree in molecular genetics and a Bachelor of Laws (Honours) from the University of Tasmania. Grant also has a Graduate Diploma of Applied Finance and Investment from FINSIA (now Kaplan).
Kathy is an experienced non-executive director and audit and risk committee chair. Kathy was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has extensive experience in the aged care and healthcare sectors, having established and led KPMG’s New South Wales Health, Ageing and Human Services audit practice from 2006 to 2018. During her 24 years with KPMG, Kathy worked in Australia, the US, Asia, and the UK. Kathy currently serves as a Non-Executive Director of 3P Learning Limited (ASX:3PL), dusk Group Limited (ASX:DSK), Capral Limited (ASX:CAA) and Alex Corporation Limited. She holds a Bachelor of Commerce (Accounting and Finance) from the University of New South Wales and is a Fellow of the Financial Services Institute of Australasia. Ms Ostin is also a graduate of the Australian Institute of Company Directors.
PR-1130-v1